<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55051">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389465</url>
  </required_header>
  <id_info>
    <org_study_id>5R01MH098260-02</org_study_id>
    <nct_id>NCT02389465</nct_id>
  </id_info>
  <brief_title>Late-Life Stress and Inflammation</brief_title>
  <acronym>S&amp;I</acronym>
  <official_title>Stress and Inflammation in the Pathophysiology of Late Life Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 18% of Americans aged 65 years and older have depression. Recent evidence suggests that
      there is a link between depression and inflammatory disease. This study investigates the
      relationship between inflammation in the brain and depression. Comparing biological and
      psychological differences in depressed and non-depressed people allows researchers to find
      better ways to treat and prevent depression. All participants will have: neuropsych tests,
      an EKG, a spinal tap, a blood draw, and, if depressed, given either an antidepressant or
      placebo for eight weeks. The investigators are trying to correlate brain function with
      depression levels and biomarkers from the blood and spinal fluid.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cytokine Levels</measure>
    <time_frame>up to week 8</time_frame>
    <description>Blood and CSF fluid will be analyzed for levels of cytokines (inflammatory proteins) including IL-6 and IL-10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>up to week 8</time_frame>
    <description>This depression rating scale will be used to determine clinical outcome for depressed participants.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm is for participants who are not depressed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental - treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depressed participants randomized to the treatment arm will be given 8 weeks of escitalopram (lexapro).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Depressed participants randomized to the placebo arm will be given 8 weeks of a sugar pill (placebo). After 8 weeks participants who are still depressed will be offered 8 weeks of escitalopram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <arm_group_label>Experimental - treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Experimental - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50-85

          -  Male or Female

          -  No clinical dementia

          -  Ability to consent

          -  English-speaking

          -  Depressed only:

          -  DSM-IV criteria for MDD

          -  HAMD &gt; 18

        Exclusion Criteria:

          -  History of relevant severe drug allergy

          -  Does not speak English

          -  Cannot give consent

          -  MRI contraindications

          -  Known primary neurological disorders

          -  Clinical dementia rating scale score &gt;0

          -  Diagnosis of a chronic psychiatric illness other than MDD

          -  Severe medical problem

          -  Current clinically significant cardiovascular disease

          -  Clinically significant abnormalities on EKG

          -  Use of an investigational drug within the past 30 days

          -  Use of Coumadin, Warfarin, or other blood thinners within the past 2 months

          -  Current treatment with psychotropic drugs or drugs that affect the CNS

          -  Current alcohol or substance abuse disorder, schizophrenia or other psychotic
             disorder, bipolar disorder, or current OCD

          -  Any other factor that in the investigator's judgment may affect patient safety or
             compliance

          -  Active suicidality or current suicidal risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma K Satchell, BA</last_name>
      <phone>215-573-0083</phone>
      <email>satchell@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Yvette I Sheline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 24, 2016</lastchanged_date>
  <firstreceived_date>February 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Geriatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
